Sanford C. Bernstein Upgrades Thermo Fisher Scientific (NYSE:TMO) to “Hold”

Thermo Fisher Scientific (NYSE:TMO) was upgraded by investment analysts at Sanford C. Bernstein to a “hold” rating in a research note issued to investors on Thursday,Zacks.com reports.

A number of other equities analysts also recently weighed in on TMO. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Morgan Stanley restated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Finally, Piper Sandler began coverage on Thermo Fisher Scientific in a report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $605.09.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $513.54 on Thursday. The firm has a 50 day simple moving average of $474.08 and a 200 day simple moving average of $520.19. Thermo Fisher Scientific has a 52 week low of $401.45 and a 52 week high of $643.99. The stock has a market cap of $190.84 billion, a P/E ratio of 28.23, a P/E/G ratio of 2.24 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts anticipate that Thermo Fisher Scientific will post 24.85 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of large investors have recently added to or reduced their stakes in the stock. Legacy Wealth Managment LLC ID raised its position in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the period. High Note Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $28,000. JPL Wealth Management LLC bought a new position in Thermo Fisher Scientific in the 3rd quarter worth $28,000. Finally, Beacon Financial Strategies CORP acquired a new position in Thermo Fisher Scientific during the 4th quarter worth $29,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.